Active surveillance of carbapenem-resistant Gram-negative healthcare-associated infections in a low-middle-income country city
Braz. j. infect. dis; 25 (2), 2021
Publication year: 2021
ABSTRACT Background:
Carbapenem-resistance in healthcare-associated infections (HCAIs) is of great concern, and it is urgent to improve surveillance. We aimed to describe and analyze HCAIs trends on Gram-negative antimicrobial susceptibility in a city from a developing country, following the implementation of an active surveillance program.Methods:
This is an aggregated study describing data from 24 hospitals with intensive care units, including a trend analysis by Joinpoint regression between January 2012 and December 2017.Results:
There were 23,578 pathogens in 39,832 HCAIs, from which 16,225 were Gram-negatives (68.8%). Carbapenem susceptibility was lowest in A. baumannii (15.4-25.9%), K. pneumoniae (51.0-55.9%), and P. aeruginosa (64.9-84.1%) and highest in E. coli (96.5-99.2%). Only K. pneumoniae showed a significant Joinpoint at 95% confidence interval: −10.71% (−18.02; −2.75) from 2012 to 2014, p = 0.02, and 6.54% (−2.00; 15.83) from 2015 to 2017, p = 0.12, which was most influenced by urinary tract infections: −9.98% (−16.02; −3.48) from 2012 to 2014, p = 0.01, and 9.66% (−1.75; 22.39) from 2015 to 2017, p = 0.09.Conclusion:
Although we found a significant change toward an improvement in carbapenem susceptibility in K. pneumoniae, resistance is high for most pathogens. These data should encourage health institutions to improve their prevention and control strategies.
Antibacterianos/farmacología, Antibacterianos/uso terapéutico, Carbapenémicos/farmacología, Atención a la Salud, Farmacorresistencia Bacteriana, Escherichia coli, Bacterias Gramnegativas, Infecciones por Bacterias Gramnegativas/tratamiento farmacológico, Infecciones por Bacterias Gramnegativas/epidemiología, Pruebas de Sensibilidad Microbiana, Espera Vigilante